Aeon Strategies Ltd. announced it cannot meet the October 28, 2026 deadline for filing its audited annual financial statements for the year ended June 30, 2026. As a result, the Ontario Securities Commission imposed a management cease trade order (MCTO) on the company's CEO and CFO, restricting their ability to trade Aeon's securities until the filings are completed. The company is working with its auditor to finalize the audit and expects to file the required documents by December 31, 2026. Other shareholders are not affected by the MCTO, and Aeon will continue to provide bi-weekly updates until the filings are submitted.
Aeon Strategies Ltd.'s ongoing management cease trade order (MCTO) status update is presented here with Pluang's Financials-sector market data as context. For readers following Financials-sector US stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 142 priced stocks, 90 rose and 45 fell today. Notable movers include ING at USD 33.75 (+1.66%), Riot Platforms Inc at USD 17.95 (+1.61%) with a typical hold time on Pluang of 18 days and a 74% sell order activity, and CleanSpark Inc at USD 6.81 (-1.45%) with a 91% buy order activity and a typical hold time of 24 days.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
